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Abstract 
Vascular complications are the leading cause of morbidity and mortality amongst diabetic patients 
which represent a major proportion of patients undergoing coronary artery revascularization. Major advances 
in drug eluting stent technologies have reduced the overall rates of restenosis in general however diabetic 
patients still remain at a high risk thus requiring target lesion revascularization more commonly as compared 
to non-diabetic cohort. Phenotypic modulation demonstrated by smooth muscle cells is essential for normal 
wound healing response however is also contributive to initiation and development of various vascular 
complications including neointimal hyperplasia which ultimately leads to the lumen re-narrowing or 
restenosis. Hyperglycemia is the hallmark of diabetes with clinical evidence of poor glycemic control 
correlated with exaggerated neointimal hyperplasia.  Although the contribution of phenotypic modulation to 
the development of restenosis has been well explored nevertheless, our understanding of this characteristic 
response in diabetic patients remains less understood. In the current study, the effects of acute and chronic 
hyperglycemia on vascular smooth muscle cell phenotypic modulation under mechanically loaded conditions 
were evaluated and current results suggests an exaggerated response in acute and chronic conditions. The 
long term goal of this project is to design an in vitro dynamic disease model which would compare cellular 
response to combined hemodynamic disturbances and metabolic abnormalities thus elucidating novel drug 
and targets aimed at reducing neointimal hyperplasia in diabetic patients. 
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Chapter 1: Introduction 
     1.1 Review of Literature 
1.1.1 Blood Vessel Anatomy: 
Blood is carried out through the body via blood vessels. Arteries carry blood away from the heart 
and branch into smaller vessels downstream. Arterioles, the smallest arteries, branch into tiny 
capillaries which are responsible for exchange of nutrients and wastes. These are connected to 
venules, which carry blood to veins and eventually return the blood to the heart [2]. A blood vessel 
comprises of three distinctive layers or tunics known as Intima, Media, and Adventitia.  
Tunica Intima: It is the innermost layer of a blood vessel and is in direct contact with blood. Intima 
is composed of specialized squamous epithelial cell layer called the endothelium. The endothelium 
is embedded on a basal lamina or basement membrane which binds the endothelium to the 
underlying connective tissue. Primary role of the basement membrane is to provide mechanical 
strength while maintaining flexibility. In addition, the permeable nature of the basement membrane 
also permits materials to pass through it. In larger blood vessels, intimal layer also consists of an 
internal elastic membrane. In large arteries, a thick layer of elastic fiber also exists at the boundary 
with tunica media called the internal elastic lamina (IEL). In addition to providing structure while 
allowing the vessel to stretch, its permeable nature permits the transport of nutrient between the 
tunics [2].  
Tunica Media: Generally the thickest layer in arteries, media consists of concentric layers of smooth 
muscle cells supported by a connective tissue network consisting primarily of elastic and 
collagenous fibers. Contraction and relaxation of circumferentially arranged muscular cells 
maintains the vascular tone of a blood vessel. During vasoconstriction, smooth muscle cells contract 
thus making the lumen narrower and increasing the blood pressure. Vasodilation leads to an increase 
in blood flow due to relaxation of smooth muscle cells which causes the lumen to widen. In large 
arteries, external elastic lamina (EEL) separates the media from the outermost layer of the blood 
vessel. [2]. 
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Tunica Adventitia: The outermost layer which comprises of a sheath of connective tissue made up 
primarily of collagenous fibers and fibroblasts. It is the thickest layer in veins. In addition to 
providing a rigid mechanical support, adventitia connects the blood vessel to the surrounding 
connective tissue [2].  
Depending on the distance from the heart, elastic fiber content in the intima and smooth muscle 
content in the media varies. Blood vessels closer to the heart, which are typically larger than 10 mm 
in diameter, are called elastic or conducting arteries. These are typically rich in elastic fibers, which 
enables them to expand and recoil with each cardiac cycle. The elastic recoil helps in maintaining 
the pressure gradient to drive the blood flow while offering a lower resistance to flow. Moving away 
from the heart, elastic fiber content in the intima of the arteries decreases while the amount of smooth 
muscle in the media increases. Such arteries range from 0.1 – 10 mm in diameter and branch into 
arterioles. These are known as Muscular or distributing arteries with a thicker media playing an 
important role in vasoconstriction [2].   
 
1.1.2 Blood Vessel Forces: With each cardiac cycle, blood is transported to the aorta for 
distribution to the peripheral arteries under pulsatile pressure. Hence, the arteries are subjected to 
circumferential and longitudinal stresses. Blood pressure exerts a force perpendicular to the vessel 
wall which leads to a circumferential stretching of the wall and the respective stress is termed as 
circumferential stress. In contrast, force exerted by the flow, induced from the pressure gradient, 
leads to a stress and strain parallel to the surface of endothelial cells known as shear stress. [3]. 
Typical mean arterial values of shear stress range from 6 to 40 dyne/cm2 but can vary from 0 to well 
over 100 dyne/cm2 in the vasculature [4-6] whereas circumferential stress in a healthy human aorta 
ranges from 1 to 2 x 106 dynes/cm2 depending upon the anatomical location [3]. Disturbances in 
these forces has been shown to affect local cellular homeostasis. Atherosclerosis, in humans, has 
been shown to be strongly correlated to sites where low time-averaged shear stress, shear stress 
reversal and spatial & temporal gradients in shear stress exist. Similarly, implants such as stents and 
3 
grafts also induce changes in the local mechanical forces and thus may also affect cellular function 
[4]. For evaluating the cellular response to altered shear stress, two common In Vitro systems have 
been used. Firstly, a parallel plate flow chamber in which cells are typically grown on a glass slide 
sandwiched between parallel polycarbonate plates. A small gap between the plates permits the 
circulation of the cell culture medium [4]. For Newtonian fluids flowing through a rectangular 
channel, wall shear stress is defined by: 
   ΤW = 6µQ 
     bh2
 where Q = volumetric flow rate, b = width of channel, h = height of channel, µ = viscosity. 
The second system involves a cone and plate system in which a fixed angle cone rotates with an 
angular velocity and for small angles, shear rate (and therefore shear stress) is essentially constant 
throughout the flow field [4]. Tension in a blood vessel is commonly represented using Laplace’s 
law given by: 
    T = Pr 
where T = Tension in the vessel wall (dynes/cm), P = Blood pressure (dynes/cm2) and r is the radius 
of the blood vessel. Wall (hoop stress, dynes/cm2), which is the normal stress in the circumferential 
direction, is given by: 
   σ θ = T/t 
where T = Tension in the vessel wall and t = wall thickness [7, 8]. 
Elastic properties of vessel wall are represented by apparent wall stiffness (or vascular compliance) 
and elastic modulus inherent to the wall. Vascular wall stiffness is expressed by the pressure-strain 
elastic modulus: 
EP = ΔPi / (ΔD0 / D0) 
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where D0 is the external diameter at pressure Pi and ΔD0 is the change in external diameter due to 
change in pressure ΔPi, at Pi. Vascular compliance is basically the inverse of wall stiffness for the 
respective area and volume components [9].  
1.1.3 Mechanotransduction: It has been well established from various studies that cells 
recognize shear stress as a stimulus and thus initiate different signal transduction cascades in 
response to stress. Endothelial cells (EC), in particular, represent a well explored example. ECs have 
been shown to change their shape from polygonal, in static cultures, to elongated upon exposure to 
flow [10, 11]. In addition, ECs also increase production of vasodilators including nitric oxide (NO) 
[12-14] and prostacyclin [15] while decreasing the release of vasoconstrictor molecules like 
endothelin [16] and angiotensin-converting enzyme [17], when subjected to shear stress. Shear 
stress also increases the anti-thrombotic & fibrinolytic activity of ECs by upregulating the 
production of thrombomodulin [18] and plasminogen activators [19, 20].  
Cells recognize mechanical forces as a stimulus through different membrane molecules and cellular 
micro-domains, which are commonly known as Mechanosensors. Typically, these include Ion 
channels, growth factor receptors, G-proteins, Caveolae, adhesion proteins, cytoskeleton, 
glycocalyx and primary cilia [19]. Ion channels of Ca2+, K+, Cl-, Na+ are activated by mechanical 
forces which leads to exchange of ions from extracellular space resulting in a change of membrane 
potential and intracellular ion concentration. G-protein coupled receptor activation increases the 
activity of adenylate cyclase (AC) and phospholipase C (PLC) which subsequently cause an increase 
in the secondary messengers like cyclic adenosine monophosphate (cAMP), Ca2+, Inositol 
trisphospate (IP3), and diaglycerol (DAG). cAMP further activates cAMP-dependent protein kinase 
A (PKA) which leads to phosphorylation of a variety of proteins. Cytosolic Ca2+ binds to calmodulin 
and activates the calmodulin-dependent kinase. IP3 binds to its receptor on the endoplasmic 
reticulum and initiates a release of Ca2+ ions form intracellular stores. DAG leads to the activation 
of protein kinase C (PKC). Tyrosine kinase receptor-activation leads to increase in IP3 and 
phosphorylation of small G proteins, such as Ras which causes activation of mitogen-activated 
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protein kinase (MAPK). In addition, cell adhesion proteins such as Integrins phosphorylate focal 
adhesion kinase (FAK) located in the focal contact with the extracellular matrix (ECM) [19]. 
Similarly, in response to cyclic stretch, mechanosensors are also responsible for signal transduction 
in vascular smooth muscle cells (VSMCs). Interaction of VSMC integrins with the ECM plays an 
important role in initiation of mechanotransduction by stretch. Response of VSMCs to stretch is 
dependent upon specific ECM molecules thus suggesting the involvement of integrins [21]. 
Activation of receptor tyrosine kinases such as platelet-derived growth factor receptor alpha 
(PDGFα) has been shown to be stretch-magnitude dependent in VSMCs. This PDGFα activation 
was shown to be independent of autocrine or paracrine release of PDGF by VSMCs [22]. In addition, 
stretch can also lead to phosphorylation of epidermal growth factor receptor (EGFR) and its 
recruitment of adaptor proteins Shc and Grb2 which, in turn, lead to extracellular-regulated kinase 
½ (ERK ½) activation [23]. Finally, stretch can also activate non-selective ion channels which allow 
the exchange of K+, Ca2+, Na+ ions [21].  
1.1.4 Atherosclerosis: Atherosclerosis is a chronic disease of the arterial wall and is the leading 
cause of death and loss of productive life years worldwide. Atherosclerotic lesions are asymmetrical 
focal thickenings of the innermost layer of the artery. They consist of cells, connective-tissue 
elements, lipids and debris. Blood-borne inflammatory and immune cells constitute an important 
part of the atherosclerotic lesion with the remainder of the cells being endothelial and vascular 
smooth muscle cells. The atheroma is preceded by a fatty streak, an accumulation of lipid-laden 
cells beneath the endothelium. Most of the cells in the fatty streak are macrophages, together with 
some T-cells [24].  
Role of Endothelial Cells: The primary role of the endothelium is to maintain vascular hemostasis 
by a variety of regulatory substances including Nitric Oxide, prostaglandins, angiotensin and 
Endothelin-1. Upon activation, endothelial cells can upregulate adhesion molecules such as 
Intercellular adhesion molecule-1 (ICAM-1), VCAM-1, P-selectin to promote the attachment and 
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rolling of circulating leukocytes and platelets. In addition to vasodilation and vasoconstriction, an 
intact endothelium inhibits platelet activation and inflammation by reducing the upregulation of 
these platelets and leukocyte adhesion molecules [25]. 
Role of Inflammatory cells:  Monocyte activation and subsequent transformation to macrophages is 
a key step involved in the development and progression of atherosclerosis. At an early stage, 
monocytes transmigrate into the intima and differentiate to macrophages. Formation of foam cells, 
a hallmark of atherosclerosis, results from uptake of oxidized LDL (oxLDL) molecules by 
macrophages. In addition, macrophages also secrete cytokines and growth factors (including MCP-
1 & MCF-7) which encourage recruitment of more leukocytes from the circulation [26]. Activation 
of macrophages subsequently leads to the release of smooth muscle growth regulatory molecules 
thus initiating migration and proliferation of smooth muscle cells.  
Role of Vascular Smooth muscle cells: Growth factors and cytokines released by platelets and 
inflammatory cells lead to phenotypic modulation of underlying smooth muscle cells leading to their 
migration and proliferation into the intima. This response continues uninhibited and is accompanied 
by accumulation of new extracellular matrix. Increased secretion of local MMPs is also contributive 
to the migration of VSMCs. In addition, VSMC are also believed to confer plaque stability as of 
fibrous caps with reduced muscle cells is more susceptible to rupture [27].   
Role of Hemodynamics: 
Various studies have demonstrated that in spite of numerous contributing factors to development of 
atherosclerosis, local hemodynamics play an extremely important role as atherosclerosis is a 
geometrically focal disease preferentially affecting the outer edges of vessel bifurcations. Focal 
propensity of atherosclerosis is believed to be mediated due to atherogenic endothelial phenotype 
as a consequence of low wall shear stress acting on these cells [28].  
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Studies with animal models and in humans have shown that focal activation of the endothelium, in 
large and medium-sized arteries, may initiate the development of atherosclerosis. Endothelial cells 
normally resist attachment of the white blood cells streaming past them, but upon activation from 
the stimulus, they express adhesion molecules that capture leukocytes on their surfaces [29]. 
Simultaneous changes in the permeability of the endothelium and the underlying matrix promote 
the entry and retention of cholesterol-containing low-density lipoprotein (LDL) particles in the 
artery wall [30]. Modification of LDL, through oxidation or enzymatic attack in the intima, leads to 
the release of phospholipids that can activate endothelial cells to express several types of leukocyte 
adhesion molecules, including vascular-cell adhesion molecule 1 (VCAM-1), which is typically 
upregulated in response to hypercholesterolemia and preferentially promotes monocyte and 
lymphocyte adhesion since they carry the counter-receptors for VCAM-1 [31]. Cheomattractants, 
produced in the underlying intima, mediate the direct migration of the bound leukocytes into the 
sub-endothelial space [24]. Monocytes entering the intima are stimulated by macrophage-colony 
stimulating factor (MCSF) to differentiate into macrophages with upregulation of scavenger-
receptors and toll-like receptors on their surface, which consequentially leads to engulfment of 
oxidized lipid molecules by macrophages to become lipid-laden foam cells [29]. Accumulation of 
lipid-laden foam cells beneath the endothelium leads to the formation of fatty-streaks, which is the 
first sign of atherosclerosis. 
Lesion progression: Macrophages engulfing the modified lipoproteins produce cytokines and 
growth factors, which in turn cause further recruitment of the macrophages and vascular smooth 
muscle cells from the underlying medial layer. In particular, interleukin-1 (IL-1) and tumor necrosis 
factor-alpha (TNF-α) stimulate the local production of PDGF and fibroblast-growth factor (FGF), 
which cause the migration and proliferation of VSMCs from the media to the intima. An important 
step in the migration and proliferation of SMCs is believed to be the secretion of the matrix 
metalloproteinases (MMPs), especially MMP-9, which are responsible for the degradation of the 
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internal elastic lamina in cerebral arteries and abdominal aorta [32]. Lipoprotein lipase released by 
the endothelium can cause proliferation of SMCs. This process involves a series of steps that include 
protein kinase-C activation and binding of lipoprotein lipase to the VSCM proteoglycans [33-35] 
and results in switching off the gene expressing the contractile proteins and switching on the genes 
for synthetic activity. Synthetic VSMCs synthesize and produce extracellular matrix [36] and help 
in further progression towards a stable atherosclerotic plaque. Acting in tandem, all of these factors 
lead to the formation of a fibro-fatty lesion [37]. A thick fibrous cap confers stability on the plaque 
by reducing the circumferential tensile stress and prevents contact between the lipid-rich necrotic 
core and the blood. However, a thin cap typically has collagen-poor structure with few SMCs but 
abundant macrophages [29] and also experience tensile stress and are predisposed to rupture [37]. 
Plaque macrophages and SMCs can also die in advancing lesion, some by apoptosis and cause 
release of extracellular lipids and cell debris which further can accumulate in the central region of a 
plaque and is often denoted as the lipid or necrotic core [29].  
Clinical complication: Plaques generally cause clinical manifestations by producing flow-limiting 
stenosis that lead to tissue ischemia or more commonly they can embolize and lodge in distal 
arteries. Inflammatory cells may hasten the plaque disruption by elaborating collagenolytic enzymes 
that can degrade collagen and by generating mediators that provoke the death of SMCs, which is 
the source of arterial collagen [38]. Production of MMPs has been identified as the most significant 
factor in this regard. In a fibrous cap, stromelysins activate other members of the family, degrade a 
broad spectrum of peptides that include proteoglycans, type IV collagen, fibronectin and laminin 
and can also destroy the matrix proteins of the cap and thus increase the likelihood of rupture [38].  
Clinical Intervention for treating atherosclerosis: 
For atherosclerotic lesions requiring surgical intervention, three main procedures are commonly 
used- Balloon angioplasty, Stenting, Coronary artery bypass graft (CABG). 
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Coronary Artery Bypass Graft: For multi-vessel lesions, diabetes mellitus, severe ventricular 
dysfunction patients, coronary arterial or vein graft is a suitable surgical procedure. In addition, 
polymeric grafts made from Dacron polyester or polytetrafluoroethylene (PTFE) are also available. 
Angioplasty: This procedures involves compression of the atherosclerotic plaque in order to restore 
flow. During this procedure, a catheter is inserted usually into the femoral artery with a deflated 
balloon on a catheter tip. The most commonly used materials for manufacturing balloons are 
polyethylene (PE) or polyethylene terephthalate (PET). Balloons are available in different diameters 
and length depending upon the lesion site.  At the lesion site, a balloon is inflated with saline 
typically to pressures of about 5-15 atm. Mechanistically, balloon expands until the deployment 
forces equals vessel wall circumferential force. The net result is reopening of the blood vessel [39]. 
Stenting: A stent is a mesh-like scaffold that prevents the negative recoil of blood vessel after 
angioplasty. The expansion of a stent to its yield strength ensures that the stent does not collapse. 
Commonly used materials for stents include stainless steel, cobalt-chromium, platinum-titanium 
alloys, nickel-titanium, tantalum alloys. In addition to providing a scaffold for prevention of 
negative recoil, stents have also been designed to slowly release drugs in order to control neointimal 
hyperplasia. First-generation drug-eluting stents include Paclitaxel eluting stents (Taxus, PES) and 
Sirolimus eluting stents (Cypher, SES). Paclitaxel cause microtubular arrest through polymerization 
of alpha and beta-tubulin in the cytoskeleton. Paclitaxel causes the cell cycle arrest at the G2/M 
phase of mitosis. In contrast, Sirolimus inhibits the mammalian target of rapamycin (mTOR) and 
thus causes cell cycle arrest at the G1 phase. A common clinical problem with first-generation DES 
was the late-stent thrombosis and inflammation in response to the thick polymer coating [40]. 
Second generation DES include zotarolimus-leuting stent (Endeavor, ZES) and everolimu-eluting 
stents (Xience V, EES) and also bio-degradable polymer coated biolimus-ES [41].   
1.1.5 Restenosis: Percutaneous coronary intervention (PCI) procedures such as balloon 
angioplasty and stenting are commonly used to treat clinical symptoms of atherosclerosis. A major 
drawback of (PCI) is restenosis of the treated vessel, resulting in renewed symptoms and the need 
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for repeat intervention. Binary angiographic restenosis is defined as the re-narrowing of the vessel 
lumen to >50% occlusion, usually within 3-6 months after PCI. Clinical restenosis is characterized 
by recurrent angina pectoris requiring target vessel revascularization (TVR) [42]. Restenosis is a 
common problem after balloon angioplasty with rates of up to 50-60% [43, 44].However, with the 
introduction of bare metal stents these rates have diminished to 20-30%  and with drug eluting stents 
it has dropped down to an overall 5-10% incidence [45]. Despite the major advances in 
interventional cardiology, restenosis remains a consistent clinical problem owing to the in-stent 
restenosis and late catch-up phenomenon with drug-eluting stents and an economic burden due to 
the large number of procedures performed world-wide annually.  
Pathophysiology: It has been suggested that restenosis is a maladaptive response of the blood vessel 
to trauma induced during angioplasty with the sequence of events– thrombosis, inflammation, 
cellular proliferation and extracellular matrix production that, in concert, contribute to post-
procedural lumen loss over approximately 6 month [46]. Lumen loss after balloon angioplasty can 
be separated into 3 distinct stages: Early loss associated with elastic recoil, late loss due to negative 
remodeling, and neointimal hyperplasia. Elastic recoil occurs immediately following angioplasty 
with reports of 34% loss in lumen diameter within 15 minutes of balloon inflation and may account 
for up to 50% of loss in the acute lumen gain after angioplasty [46-49].  
Fracture of the atherosclerotic plaque exposes the thrombogenic contents to the bloodstream thus 
triggering platelet adhesion, activation and thrombosis. This is further complicated by the 
denudation of the endothelium which leads to the loss of antithrombogenic factors like Nitric oxide 
(NO), prostacyclin and tissue plasminogen activator. Platelets, upon activation, release mitogens 
including thromboxane A2, serotonin and platelet-derived growth factor (PDGF) which leads to 
phenotypic modulation of medial smooth muscle cells resulting in their migration to the intima, 
proliferation and synthesis of extracellular matrix [46]. Negative remodeling may also contribute to 
the development of restenosis as replacement of hyaluronic acid with collagen in the extracellular 
matrix is believed to result in scar contraction [50, 51].  
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With stents, elastic recoil is virtually eliminated and neointimal hyperplasia is the main mechanism 
responsible for lumen narrowing after stent implant and thus in the development of in-stent 
restenosis [52]. Cellular mechanisms leading to development of in-stent restenosis (ISR) have been 
described to be a part both the early and late phase of the complication. The early phase, immediately 
after the intervention, is associated with relocation of plaque, reorganization of thrombus and an 
acute inflammatory response. Thrombus formation seems to be a consequence of the endothelial 
disruption [53] thus leading to deposition of fibrin and platelets at the site of injury which invoke 
an inflammatory response. Consequently, an increased leukocyte trafficking is evident at the stent 
location with subsequent migration into the media [54]. Increased production of adhesion molecules, 
cytokines, chemoattractants and growth factors by corroborating platelets, monocyte/macrophages 
and SMCs in turn results in an increased recruitment of inflammatory cells. With the onset of the 
late phase, phenotypic modulation of VSMCs results in their migration into the intima and 
subsequent proliferation. Extensive extracellular matrix (ECM) production by dedifferentiated cells 
is responsible for the increasing volume of the intimal tissue with the bulk of the neointimal tissue 
comprising primarily of proteoglycans and collagen with late lesions consisting of only about 11% 
cellularity [55, 56]. 
The advent of Drug-eluting stents (DES) has reduced the overall rates of restenosis as compared to 
Bare-metal stents (BMS) alone. However, with the increasing use of DES, especially  in complex 
lesions such as lesions in left main artery, bifurcations, small vessel vein grafts, chronic total 
occlusions and diabetic patients, ISR rates of up to 10% have been reported [57, 58]. The time frame 
to restenosis after DES may be longer as compared to BMS due to the application of anti-
proliferative drugs with repots of up to 12 months [59]. Various factors, similar to BMS, have been 
implicated in the development of ISR with DES including diabetes, lesion length, vessel diameter, 
implantation factors. In addition to these, factors such as resistance to antiproliferative drugs, 
hypersensitivity reactions to the polymer and metal, circulating levels of MMPs, low wall shear 
stress, polymer release kinetics have also been demonstrated to be contributive to ISR development 
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[60]. Further, different types of DES have also been shown to affect the phenotype of VSMCs with 
synthetic phenotype more frequent with BMS and paclitaxel-eluting stents (PES), intermediate with 
Zotarolimus-eluting stent (ZES) and Sirolimus-eluting stents (SES), contractile with tacrolimus-
eluting stent (TES) [61].  
Role of Endothelial Cells: Mechanical injury from coronary intervention leads to denudation of the 
endothelium and subsequently leads to a sequel of events resulting in VSMC migration and 
proliferation. Re-endothelialization is a critical step to completion of the wound healing response to 
PCI-induced injury of the vessel wall. Endothelial dysfunction is commonly observed at sites of 
regenerating endothelium. Studies with drugs that enhance endothelium-derived relaxing factors or 
diminish endothelium derived contracting factor production have been shown to control restenosis 
[62]. Further, the extent of the denuded area is also contributive to re-endothelialization and hence 
intimal hyperplasia as small denuded areas heal more quickly [63]. 
Role of Platelets, Macrophages and VSMCs: Proliferation and migration of vascular smooth muscle 
cells from the medial layer over time results in the formation of neointima.  As described previously, 
increased trafficking of inflammatory cells and platelets at the site of injury leads to an increase in 
local concentration of growth factors and cytokines which stimulate phenotypic modulation of 
VSMCs possibly due to degradation of the basement membrane via MMPs secreted by 
macrophages.  
Role of Hemodynamics: In stented vessels, low wall shear stress has been inversely correlated with 
neointimal thickening using 3D-reconstruction and finite element analysis [64, 65]. Further, 
Wenetzel et al also showed similar results in 14 patients after stent implantations in coronary arteries 
[66]. VSMCs respond to shear stress variations such that low wall shear stress is contributive to 
VSMC proliferation and hence neointima formation whereas high shear shows an opposite effect 
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[67].Further evidence exists in studies where reduced number of stent wires and strut thickness have 
resulted in less of vessel area exposed to low shear stress [68].  
Classification of In-Stent Restenosis Lesions: Based on angiographic patterns, restenotic lesions 
have been classified as Focal (Type Ia or at articulation/gap, Ib or at stent margin, Ic or at focal 
body, Id or multifocal) and Diffuse (Type II, III and IV). Type I lesions are typically ≤ 10 mm in 
length and may be located at the unscaffolded segment (Type Ia) or at the body of the stent (Type 
Ib), proximal or distal margin of the stent (Type Ic) or combination of these sites (Type Id). Type II 
lesions or diffuse-intrastent are > 10 mm in length and are confined to the stented area without any 
distal or proximal extensions. Type III or diffuse proliferative are lesions > 10 mm in length and 
extend beyond the stent margin. Type IV or total occlusion represent lesions with no flow and 
require immediate revascularization [69].  
Predictors of Restenosis: Three major classes of factors, which serve as predictors of restenosis, 
have been defined- Patient-related factors, Vessel-related predictors and Procedure-related factors. 
Various patient-related factors including high serum levels of C-reactive protein (CRP) & 
Interleukin-6 (IL-6), previous angioplasty. However, the most consistent patient-related factor is the 
presence of Diabetes with a 30-50% increased risk of developing restenosis. Vessel-related factors 
such as vessel diameter and lesion length independently serve to predict the incidence of in-stent 
restenosis with larger diameter/shorter lesions demonstrating significantly lower restenosis rates 
[70]. Finally, procedure-related factors such as stent-strut thickness, stent fracture, stent length and 
minimum lumen diameter serve as significant clinical predictors of restenosis [58]. Thinner-struts 
are hemodynamically more favorable as compared to thicker struts. With increase in stent length, 
rate of In-stent restenosis (ISR) have been reported to be nearly double for stent lengths > 35 mm 
[71].  
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1.1.6 Vascular Smooth muscle cells biology: 
Vascular smooth muscle cells (VSMCs) are primarily responsible for establishing and orchestrating 
contraction and distension in blood vessels. VSMC maintain contractile tone by a highly organized 
architecture of contractile/cytoskeletal proteins and associated regulatory components within the 
cell cytoplasm and establish distensibility by synthesis, secretion and organization of the 
extracellular matrix (ECM) components with elastic recoil and resilience properties. The primary 
function of vascular smooth muscle cells is to maintain the vascular tone via contraction and 
dilation. VSMCs expresses a variety of contractile proteins, ion channels and signaling molecules 
that regulate its contraction. [72]. Upon contraction VSMCs shorten, thus decreasing the diameter 
of a blood vessel to regulate the blood flow and pressure. Changes in the cytosolic calcium ion 
concentration or [Ca2+] are the principal mechanisms that regulate the contractile state of VSMCs 
[73]. 
The contractile proteins in a VSMC are packed into thin and thick filaments: thin filaments are 
composed of Actin, Tropomyosin and specific thin filament-binding proteins (e.g. caldesmon, 
Calponin), while the thick filaments are composed of myosin. Upon receiving contractile stimuli, 
there is an increase in the cytosolic calcium ion concentration [74].  When cytosolic [Ca2+] exceeds 
1 µM, calcium ions bind to calmodulin (CaM), with four calcium ions binding to each calmodulin, 
leading to a conformational change in CaM. In the altered conformational state, the 4Ca2+ - CaM 
complex binds to and activates myosin light-chain kinase (MLCK). The active kinase complex, 
4Ca2+ - CaM – MLCK, subsequently phosphorylates myosin at 20-kD myosin light chain (MLC20) 
on serine 19 thus allowing myosin adenosine triphosphatase (ATPase) to be activated by actin which 
leads to contraction of the muscle as a result of MgATP-dependent cyclic interactions of myosin 
with actin [73, 75, 76]. The myosin molecules extend from the thick filaments to bind to actin via 
cross—bridges and on association with actin, myosin converts chemical energy (ATP) into 
movement of the heads (attached to actin) which exerts force on the thin actin filaments and causes 
shortening of the VSMCs [74]. However, when the cytosolic concentration of Ca2+ falls below 1 
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µM, due to the cellular extrusion or uptake by sarcoplasmic reticulum (SC), CaM dissociates from 
MLCK thus causing its inactivation. During these conditions, myosin phosphatase dephosphorylates 
MLC20 and leads to relaxation by inactivating actomysoin ATPase (actin-activated, ATPase 
activity of myosin). Dephosphorylating activity of myosin phosphatase is independent of the 
cytosolic [Ca2+] [74].  
VSMCs within the vascular continuum have the ability to adapt to extrinsic and intrinsic cues during 
different developmental stages and in disease response to an injury stimulus. This ability is due to a 
phenomenon known as the phenotypic modulation and is a major feature that distinguishes VSMCs 
from terminally differentiated skeletal muscle cells and cardiomyocytes [72].   
Contractile phenotype: Contractile-state VSMCs are characterized by a range of contractile 
proteins, contractile-regulating proteins, contractile agonist receptors and signaling proteins 
responsible for contraction and maintenance of vascular tone. In addition, contractile smooth muscle 
cells (SMCs) are elongated, spindle –shaped cells in culture composed of tightly bundled 
myofilaments and minimal rough endoplasmic reticulum, Golgi or free ribosomes [72]. These cells 
exhibit a low proliferation index. The expression patterns of a wide range of protein markers have 
been characterized to describe the phenotypic state of SMCs. Since contractile SMCs exhibit a 
mature contractile apparatus, proteins, which are predominantly involved in SMC contraction, also 
serve as the contractile state markers. These include smooth muscle α-Actin (SMαA), smooth 
muscle myosin heavy chains SM-1 and SM-2, Calponin, SM-22α and Smoothelin and h-caldesmon 
[77]. In addition to contraction-related protein expression, contractile VSMCs exhibit differential 
levels of extracellular matrix (ECM) components (increased type I and IV collagen) and decreased 
matrix metalloproteinases (MMPs) and increased tissue inhibitors of MMPs (TIMPs) [72]. 
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Synthetic/dedifferentiated: During non-pathological processes such as normal vascular development 
or upon injury VSMCs exhibit a dedifferentiated/synthetic phenotype, characterized by high rate of 
proliferation, migration and production of ECM components. Synthetic VSMCs also demonstrate a 
decreased expression of contractile-state associated proteins (SMMHC, SMαA, Calponin, SM-22α 
etc.) with concomitant increased expression of osteopontin, 1-caldesmon, non-muscle myosin heavy 
chain, vimentin, tropomyosin 4 and cellular-retinal binding-protein-1 (CRBP-1) [72]. 
Morphologically, synthetic VSMCs have increased cell size and exhibit hill-valley morphology in 
culture. Ultrastructure of these cells shows a cytoplasm devoid of contractile bundles with extensive 
rough endoplasmic reticulum, Golgi and ribosomes [78]. Phenotypic modulation of vascular smooth 
muscle cells plays a major role in development of progression of various diseases including 
Atherosclerosis, Hypertension, Vascular calcification and in the healing response to mechanical 
injury to the vessel wall [79]. 
1. Atherosclerosis: Vascular smooth muscle cell phenotypic modulation is a critical
contributor to the development of atherosclerosis. Medial VSMCs are believed to undergo 
phenotypic modulation and migration into the intima, where they proliferate and secrete 
copious amounts of extracellular matrix and thus participate in fibrous cap formation [80]. In 
addition, a general consensus on  increased VSMC content conferring atherosclerotic plaque 
stability also exists [79]. 
2. Systemic Hypertension: It is clinically defined as a sustained diastolic pressure of > 90
mmHg or systolic pressure > 120 mmHg. The exact mechanism of systemic hypertension is not 
completely known however a common feature is increase in the peripheral resistance, as a result 
of increased vascular tone/SMC contractility and vascular remodeling [81]. Increased 
intracellular calcium handling/release and changes in membrane polarizations have been shown 
to be contributive to increased contractility [81, 82].  
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3. Vascular Calcification: It involves increased levels of calcium deposition in major arteries
resulting in an impaired vascular compliance and recoil in the aorta and muscular arteries in 
general and in response to balloon dilation [83, 84]. Vascular calcification promotes systolic 
hypertension, coronary insufficiency and intensifies cardiac energy demand. It also promotes 
ischemia and serves as a predictor for amputation [85]. Molecules that characteristically 
regulate osteoblast differentiation and bone formation including osteogenic transcription factor 
Runx2, osteopontin, osteocalcin, type I collagen and BMP-2 have been found in calcifying 
vessels [86, 87]. In the presence of increased phosphate levels, BMP-2 has been shown to 
increase phosphate transport across VSMCs in a dose-dependent manner, thus promoting 
osteogenic phenotypic transition of SMCs [88]. In addition, bovine aortic smooth muscle cells 
(BASMCs) have been demonstrated to loose contractile lineage markers after culturing in 
calcifying conditions [89].  
4. Aneurysms: These are defined as a weak area in the wall of a blood vessel that leads to
widening or ballooning of the artery. Studies have shown reduced expression of contractile-
state markers in VSMCs and concomitant increase in MMP-2 and MMP-9 in animal models 
and human aneurysms. These events were shown to occur before the formation of aneurysms 
[90].  
1.1.7 Diabetes-related complications 
Diabetes remains the seventh leading cause of death in the United States with nearly 1.7 million 
new cases of diabetes are reported every year leading to a total economic burden of about $245 
billion in direct and indirect healthcare costs [91]. Cardiovascular disease account for about 68% of 
diabetes-related deaths annually as patients with diabetes have a four to six-fold increased risk for 
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cardiovascular events in comparison to non-diabetic patients and appear to develop more severe 
coronary artery disease  [92].  
Pathology of diabetes and types 
Diabetes encompasses a range of disorders like Type 1 Diabetes Mellitus (T1DM), type 2 diabetes 
mellitus (T2DM), gestational diabetes mellitus, drug-or chemical induced diabetes ( for example 
from some second-generation antipsychotic drugs and some anti-human immunodeficiency virus 
(HIV) drugs as well as exposure to combination antiretroviral therapy) [93]. However, majority of 
the cases of diabetes are of type 2. 
Type 1 diabetes is characterized by a long preclinical period of autoimmune attack on the beta cells, 
carried out by autoreactive T-cells and marked by the emergence of autoantibodies against β-cell 
autoantigens. Type 1 diabetic patients are unable to secrete insulin in response to a glucose load and 
thus eventually become hyperglycemic [94].  
T2DM patients or non-insulin dependent diabetes is due to desensitization of insulin receptors. It 
develops slowly and at an early stage is characterized by the development of insulin resistance. This 
is associated with a reduction in glucose uptake by target cells and an altered lipid metabolism. 
Hyperinsulinemia, hyperglycemia and dyslipidemia area common features of T2DM and as the 
disease progresses, β-islet cell function becomes impaired and eventually fails, signaling the 
development of overt type 2 diabetes [95]. 
Diabetes and Atherosclerosis 
The histological course of atherosclerosis in diabetes is nearly the same as for non-diabetic patients. 
However, atherosclerotic plaques in the presence of diabetes demonstrate higher levels of vascular 
calcification, greater number of necrotic cores, increased expression of receptor for advanced 
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glycation end-product (RAGE) on endothelial and smooth muscle cells and increased macrophage 
and T-cell infiltration [25]. Coronary atherectomy specimens collected from diabetic patients 
demonstrated that patients with diabetes exhibited a larger content of lipid-rich atheroma than those 
without diabetes [96]. In addition, carotid endarterectomy specimens from Type 2 diabetic patients 
were shown to be richer in macrophages and T-lymphocytes with increased expression NF-κB and 
MMPs [97].    
Role of Dyslipidemia 
Elevated triglycerides, reduced high density lipoprotein cholesterol (HDL-C) concentrations and 
elevated levels of free fatty acids (FFA) define the characteristic lipid profile in diabetic patients. 
Increased triglycerides can be attributed to a functional defect in the enzyme lipoprotein lipase 
which is involved in hydrolyzing fatty acids from triglycerides. A functional defect in the enzyme 
has been associated with diabetes thus leading to a decreased expression of apolipoprotein A-I and 
thus HDL particles. In addition, expression and activity of an endothelium bound phospholipase, 
endothelial lipase, is also involved in catabolizing HDL thus further reducing their level. Further, 
hepatic dysregulation as a consequence of a fatty liver, hyperinsulinemia, and hyperglycemia 
exacerbates the lipid metabolism. LDL particles in T2DM are considered to be more pathogenic 
since these particles are smaller, denser and hence more prone to entry, oxidation and retention in 
the blood vessel [98].  
Elevated thrombotic response 
 Diabetes is associated with a pro-thrombotic state characterized by platelet hyperactivity, increased 
coagulation and impaired fibrinolysis [99]. High glucose has been reported to cause increased 
platelet reactivity by increased PKC activation followed by subsequent granule release & 
aggregation [100], non-enzymatic glycation of proteins on the surface of the platelets [101]. Further, 
hyperglycemia mediated redox imbalance leading to an increase in reactive oxygen species has been 
shown to affect the activity of calcium ATPases [102] thus increasing the intracellular calcium levels 
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in platelets and reducing cAMP levels consequently leading to an increased aggregation and 
activation of platelets. Increased activation of pro-thrombotic coagulation factors such tissue factor, 
Factor VII, XIII has been reported in T2DM [98]. 
Endothelial Dysfunction 
The endothelial layer provides a physical barrier to blood flow from the vessel wall. It also controls 
homeostatic processes including blood pressure, hemostasis and homing of immune cells to the sites 
of inflammation. It produces mediators that induce vasoconstriction including endothelin, 
prostaglandins, and angiotensin II [103]. ECs produce nitric oxide using L-arginine by the action of 
eNOS in repose to blood flow changes [104]. The balance between vasodilation and 
vasoconstriction is fundamental to maintenance of the arterial pressure. In case of diabetic patients, 
metabolic complications like hyperglycemia, elevated free fatty acid levels, increased ROS 
production, insulin resistance lead to endothelial dysfunction which manifests as impairment of NO-
dependent vasodilation [98]. Dysfunctional endothelial cells are associated with an increased 
adhesion of circulating leukocytes and platelets via upregulation of adhesion receptors and also 
exhibit an increased LDL permeability and retention thus contributing to the development of 
atherosclerosis in diabetes [103].   
Role of Inflammatory cells 
Type 1 diabetes has been shown to cause an increase in circulating inflammatory markers such as 
C-reactive protein, soluble intercellular adhesion molecules, CD 40 ligand [105-107]. In addition,
T1D also promotes an increase in IL-6, Il-8, IL-1α. Further, release of saturated fatty acids also 
promote the release of pro-inflammatory cytokines by monocytes in case of T2D [107]. In animal 
models of atherosclerosis, hyperglycemia has been shown to accelerate influx of inflammatory 
markers through the TGF-β signaling pathway [108]. 
Role of Vascular Smooth muscle cell 
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Although the main role of VSMCs in atherosclerosis involves their phenotypic modulation, 
migration to suboptimal space, proliferation and extracellular matrix synthesis thereby enlarging the 
neointimal lesion. VSMCs grown in vitro under high glucose conditions demonstrated an increased 
proliferation, migration hypertrophy and higher ECM production in comparison to low glucose 
conditions [109, 110]. VSMC from diabetic mice exhibited an increased expression of 
proinflammatory gene expression including MCP-1 and IL-6 [111, 112]. Thus diabetic state 
predisposes VSMCs to the development of atherosclerosis.  
Diabetes and Restenosis 
The state of diabetes has been consistently reported as the main patient related risk factor for 
developing restenosis after PCI in various clinical trials. Van belle et al reported restenosis rates to 
be almost twice as much as in non-diabetic patients (63% vs. 36%) at 6 month follow up of balloon 
angioplasty. Initial observations correlated late vessel occlusion with increased restenosis in these 
patients however after excluding patients with late occlusion, restenosis rates were still higher in 
diabetic patients [113] suggesting involvement of additional mechanism such as negative 
remodeling acute recoil and greater neointimal response.  
Clinical trials comparing restenosis rates between diabetic and non-diabetic patients have 
demonstrated higher rates of both angiographic restenosis (diameter stenosis ≥50% determined 
angiographically)  [114-117] and clinical restenosis (requiring target lesion revascularization) [115, 
118, 119]. As mentioned previously, restenosis after stent implantation is primarily due to an 
exaggerated neointimal hyperplasia and increased tissue proliferation has been reported with serial 
IVUS analysis in diabetic patients [120].  
Use of first generation drug-eluting stents reduced the overall rates of restenosis when compared to 
bare-metal stents alone in all patients including those affected by diabetes [121-123]. However, 
emergence of stent thrombosis became a safety concern with these devices. Studies have reported a 
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significant difference in the survival rate favoring BMS over Sirolimus eluting stent (SES) with a 
lower survival rate for patients with diabetes. This difference was not observed in patients without 
diabetes [124] with additional evidence from studies reporting higher death rates due to cardiac 
causes in diabetic patients treated with SES [125]. As compared to SES, paclitaxel eluting stents 
have been reported to have higher cases of Stent thrombosis in diabetic patients at 1 year [126, 127]. 
In addition, rates of restenosis remained highest for diabetic patients requiring insulin treatment, 
irrespective of stent type [128]. Second-generation of drug eluting stents had an optimized drug 
deliverability while seeking to minimize target lesion revascularization (TLR) and ST. A summary 
of clinical trials comparing the efficacy of different DES in diabetic patients are listed in table 1 [1]. 
Diabetic patients still represent a high risk patient population with patients requiring insulin therapy 
being the most affected [1].  
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  Trial Conclusion 
SYNTAX (TAXUS) [129] Increased MACE (Major adverse cardiac events) 
after PCI  
FREEDOM 2 (TAXUS) [130] CABG (Coronary artery bypass grafting) better 
for all cause morality, MI (Myocardial 
Infarction), stroke 
SPIRIT V 3 (Xience V vs 
TAXUS) [131] 
Paclitaxel-eluting stents (PES) increased In-stent 
late loss 
Pooled analysis of SPIRIT 
II,III,IV and COMPARE 4 
(TAXUS) vs. Xience V EES 
[132] 
No difference in safety or efficacy of Endeavor 
Everolimus-eluting stents (EES) vs. PES in 
diabetic patients when EES led to decreased 
mortality, MI, ST (Stent thrombosis) and TLR 
(Target-lesion revascularization) in non-diabetic 
patients.  
ENDEAVOR IV [133] In-stent restenosis (%) increased in patients 
with Diabetes treated with E-ZES (Zotarolimus-
Eluting Stent). 
E-FIVE [134] Diabetic Patients had significantly higher rates 
of MACE, TLR, TVF (Target vessel failure) 
and ST as compared to non-diabetic at 1 year.  
NAPLES-DIABETES [135] E-ZES led to increased 3 year rates of MACE
due to higher rates of TLR. 
Pooled Analysis of 
International global 
RESOLUTE program [136] 
Insulin treated patients affected by significantly 
high Target lesion failure (13.7%). 
Table 1.1: List of clinical trials comparing efficacy of drug eluting stents 
in diabetic patients [1].  
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Characterization of restenotic lesions at 1 year after DES implantation by optical coherence 
tomography revealed thicker neointima in case of diabetic patients with direct correlation of 
glycemic control (HbA1C levels) and neointimal thickness. Further, incidence of low signal pattern 
in poor glycemic control group was significantly higher thus demonstrating large amounts of 
extracellular matrix and proteoglycans in these lesions [137] eventually increasing the risk of stent 
thrombosis [1].  
Contribution of Hyperglycemia 
Evidence for contribution of hyperglycemia to development of restenosis comes from clinical 
studies demonstrating a poor glycemic control associated with increased restenosis due to higher 
rates of target lesion revascularization. In addition to long-term glycemic control, pre-procedure 
hyperglycemia has been demonstrated to be strongly correlated with restenosis in diabetic patients 
since diabetic patients with pre-procedure hyperglycemia (> 128 mg/dl) had a 33.8% target-vessel 
revascularization (TVR) rate at 9-month follow up [138, 139]. Furthermore, pre-procedural 
hyperglycemia was independent of glycated-hemoglobin (HbA1C) levels as diabetic patients with 
HbA1C ≤ 7% but pre-procedure glucose levels > 128 mg/dL had significantly higher rates of TVR 
as compared to HbA1C ≤ 7% & pre-procedure glucose < 128 mg/dL [140]. Similar results were 
found by Nusca et al where pre-procedure hyperglycemia was correlated with increased rates of 
target vessel failure (TVF) [141]. Hyperglycemia may mediate these effects via differential response 
of various cellular components involved in development and progression of neointimal hyperplasia 
and our current understanding of these remains less well understood.   
Mechanism of restenosis involves denudation of the endothelium followed by attachment of 
platelets and inflammatory cells at the site of injury which leads to an increase in local growth factors 
and inflammatory markers thus affecting VSMC migration and proliferation.  Hyperglycemia has 
been shown to affect all of these processes.  
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Hyperglycemia has been shown to increase activation and aggregation of platelets via increase in 
PKC activation [100], direct osmotic effects [142] and by induction of non-enzymatic glycation of 
platelet-surface proteins [143]. In addition, acute hyperglycemia has been shown to cause an 
increased expression of P-selectin and CD40 ligands by platelets [144, 145]. Further, hyperglycemia 
mediated advanced glycated-end products (AGE) & reactive  oxygen species (ROS) production can 
lead to elevated expression of procoagulant tissue factor by endothelial cells via activation of NF-
κB [146]. This mechanism also plays an important role in hyperglycemia mediated reduction in 
tissue p[plasminogen activator (t-PA), ultimately promoting thrombosis [147].   
As a part of vascular healing, endothelial progenitor cells (EPC) have been demonstrated to play an 
important role in re-endothelialization of blood vessels post injury with studies demonstrating the 
approach of capturing circulating EPCs contributive to accelerated re-endothelialization [65]. 
Diabetes has been related to delayed re-endothelialization in animal models [148]. Human EPC 
subjected to high glucose (12.5 mM) have been shown to induce senescence via phosphorylation 
p38 MAPK [149] thus serving as a potential mechanism for impaired re-endothelialization 
associated with diabetes.  
Vascular smooth muscle cell migration and proliferation in the intima is a key event in the 
development of neointimal hyperplasia and restenosis. Significant in vitro evidence exists on direct 
effects of high glucose in causing vascular smooth muscle proliferation via upregulation of growth 
factors such basic FGF (bFGF), Transforming growth factor alpha (TGF-α) [150, 151], upregulation 
of osteopontin release [152] , increased polyol pathway flux [153], upregulation of protein kinase C 
[154], increased DNA synthesis [155], increased IGF-1 responsiveness resulting in enhanced 
proliferation and migration [156], suppression of AMP activated protein kinase (AMPK) resulting 
in activation of mammalian target of rapamycin (mTOR)  [157, 158], upregulation of MAPK, 
PI3K/Akt and NF-κB [159]. In addition animal models of type 2 diabetes reported a significantly 
higher cell proliferation at 3 days post arterial injury as compared to controls [160]. Although 
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contradictory results have been reported in models of type I diabetes with no difference [161] and 
significant difference in contribution of hyperglycemia to neointimal thickness [162], these 
differences have been attributed to the extent of streptozotocin treatment. Thus, hyperglycemia 
independently may contribute to neointimal hyperplasia [153]. Additionally, hyperglycemia has also 
been reported to increase SMC migration via PKC dependent pathway [163].  
1.2 Clinical Significance: 
Diabetes represents one of the major global health issues with nearly 1.7 million new cases reported 
each year. These patients are at a four-to-six fold increased risk of developing cardiovascular 
diseases with reports of up to 68% of deaths associated with it. Diabetic patients are more vulnerable 
to restenosis due to a greater need for revascularization. However, prognosis of PCI in diabetic 
patients remains consistently poor with the state of diabetes being the most consistent patient-
specific predictor of developing Restenosis. Major advances in stent technology, with the advent of 
drug-eluting stents, have reduced the overall rates of restenosis when compared to bare-metal stent 
alone however restenosis rates for diabetic patients are still higher when compared to their non-
diabetic counterparts.   
Development of restenosis post-angioplasty is primarily due to negative recoil of the blood vessel 
in response to balloon distension. Restenosis after implantation of stents is primarily due to the 
development of Neointimal hyperplasia (NIH). The exact mechanisms that trigger NIH are not 
completely understood however phenotypic modulation of vascular smooth muscle cells plays a key 
role in the development of neo-intima.  
Vascular smooth muscle cells possess a unique characteristic of switching their phenotype in 
response to the external stimulus. Although the plasticity exhibited by these cells is critical for 
wound healing, this remarkable capacity of the cells is also contributive to the development of 
cardiovascular diseases such Atherosclerosis, Vascular calcification, Aneurysms, Hypertension and 
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Restenosis. Exposure to a stimulus, leads to dedifferentiation of smooth muscle cells from a 
contractile/quiescent state to a synthetic state. Synthetic smooth muscle cells are characterized by 
their higher rate of proliferation, increased migratory capacity, loss of contractile-state associated 
proteins, increased synthesis of extracellular matrix molecules, increased expression of matrix 
metalloproteinases, and increased expression of osteoblast-like cell markers. Mechanical injury 
from PCI procedures have shown to cause denudation of the endothelium thus exposing medial 
smooth muscle cells to shear forces from blood flow in addition to a myriad of circulating growth 
factors. These events signal medial smooth muscle cells to dedifferentiate into a synthetic 
phenotype, migrate to the intima and proliferate.   
Although the contribution of phenotypic modulation to the development of restenosis has been well 
explored nevertheless, our understanding of this characteristic response in diabetic patients remains 
less understood. The current study attempts to further our understanding in this domain and proposes 
a dynamic-disease model to explore the influence of diabetes-related hyperglycemia on phenotypic 
modulation of smooth muscle cells by subjecting SMCs to clinically relevant mechanical forces in 
the presence of high glucose conditions.  
1.3 Project Aim: 
This study was aimed at developing an In Vitro disease model to compare vascular smooth muscle 
cell response to two clinically relevant pathological stimuli- Low wall shear stress and 
Hyperglycemia. As a secondary aim, we also compared VSMC response in acute hyperglycemic 
condition with long-term conditioned chronic hyperglycemia when subjected to cyclic strain and 
low wall shear stress.  
28 
Chapter 2 
“Effects of clinically relevant mechanical forces on hyperglycemic vascular smooth muscle 
cells: An In Vitro Dynamic Disease Model” 
2.1 Introduction: 
Cardiovascular diseases account for about 68% of diabetes-related deaths and with nearly 1.7 
million new cases of diabetes reported each year resulting in considerably high economic burden 
[3]. Patients with diabetes have a four to six-fold increased risk for cardiovascular events in 
comparison to non-diabetic patients and appear to develop more severe coronary artery disease [92]. 
Outcomes of percutaneous coronary interventions (PCI) have been reported to be less favorable in 
case of diabetic patients [113, 164]. The increased risk of restenosis in diabetic patients has been 
attributed to an exaggerated intimal hyperplasia eventually leading to a greater late lumen loss and 
decreased vessel lumen area [120]. Drug eluting stents have successfully reduced the overall rates 
of restenosis however diabetic population remains at a higher risk group with reports demonstrating 
higher rates of restenosis associated with diabetes [165]. 
Barotrauma from a percutaneous coronary intervention (PCI) causes endothelial denudation and 
consequently exposes underlying smooth muscle cells to a myriad of circulating growth factors and 
promotes a phenotypic shift of vascular smooth muscle cells (VSMCs) from contractile to synthetic 
state, which is characterized by an increased capacity of VSMCs to migrate and proliferate from the 
medial layer to form the neointima followed by increased secretion of extracellular matrix [166]. 
Phenotypic modulation is considered to be one of the key mechanisms responsible for initiation and 
progression of neointimal hyperplasia and restenosis. In addition to growth factors, hemodynamic 
forces such as wall shear stress from blood flow and cyclic strain also control the phenotype and 
function of VSMCs [167].  Physiological levels of cyclic strain (≤ 10%, 1Hz) mimicking an in vivo 
environment have been shown to promote quiescent, contractile phenotype of VSMCs [168] in 
contrast to high strain rates which have been shown to promote SMC proliferation and 
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dedifferentiation [169-171]. In case of endothelial injury or vascular smooth muscle cell migration 
into the intima, blood flow may directly act on the superficial layer of VSMCs [167]. Shear forces 
have been shown to have direct effects on phenotypic modulation of vascular smooth muscle cells 
with physiological shear stress (5-25 dynes.cm-2) reducing proliferation and promoting contractile 
phenotype [172, 173] and low wall shear stress leading to SMC proliferation [174] and migration 
via upregulation of platelet-derived growth factor (PDGF) [175]. Additionally,  in vivo and clinical 
studies have demonstrated areas of low wall shear stress to be associated with thicker neointima 
[176, 177].  
Hyperglycemia is the hallmark of diabetes with clinical evidence of its association with higher rates 
of target lesion revascularization (TLR) amongst diabetic patients [138, 139]. Furthermore, 
preprocedure hyperglycemia, independent of glycated hemoglobin (HbA1C), has been demonstrated 
to be strongly correlated with restenosis in diabetic patients [140]. Contributive effects of 
hyperglycemia in neointimal thickening have also been demonstrated in animal models of type I 
diabetes [162]. At a cellular level, exposure of SMCs to high glucose conditions has been 
demonstrated to show hyperproliferation [154, 178-180], hypertrophy [154] and enhanced migration 
[181, 182].  
Although various studies have implicated a pro-restenotic response of VSMCs to hyperglycemia, 
cellular response to hyperglycemia in combination to mechanical forces and thus injury-mediated 
response in diabetic patients is not completely understood. Thus, we hypothesize that exposure of 
clinically relevant mechanical forces under chronic hyperglycemic conditions will lead to a greater 
phenotypic modulation of vascular smooth muscle cells. Further, results from the current study will 
be compared to prior art in order to determine the relevance of our dynamic disease model.  
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2.2 Materials and Methods: 
Cells cultured on type-1 collagen coated silicone membrane were subjected to static-control (U) or 
Cyclic Tensile (CT) stress or cyclic tensile and low wall shear stress (CTS). Mechanical loading 
was performed on a previously designed custom simulator set up, which enables application of 
cyclic tensile stress and low wall shear stress on cultured cells. Cells were subjected to either 
physiological cyclic strain (0-7%) at 1 Hz for 24 hours (CT) or to cyclic tensile strain and low wall 
shear stress (CTS, ~0.30 dynes.cm-2) from externally supplied flow at 350 mL/min using a peristaltic 
pump for 24 hours (CTS). Cyclic strain was applied using FlexCell-3000™ system (Flexcell 
International, NC).  Cells cultured on type-1 collagen coated silicone membranes in a 12-well plate 
served as static controls (U). All experimental groups are summarized in table 2.1. 
Unloaded/Static Cyclic Tensile Cyclic Tensile + Shear 
Low glucose LG U: Cells subjected 
to 5.5 mM D-glucose  
LG CT: Cells subjected 
to 5.5 mM D-glucose 
under cyclic strain (0-7% 
at 1Hz, 24 hr) 
LG CTS: Cells 
subjected to 5.5 mM D-
glucose under cyclic 
strain (0-7% at 1Hz) and 
shear from flow (~ 0.3 
dynes.cm-2) 
Acute high 
glucose 
AG U: Cells subjected 
to 25 mM D-glucose for 
84 hours 
AG CT: Cells subjected 
to 25 mM D-glucose for 
84 hours (36 hrs. seeding 
+ 24hrs. quiescence + 24
hrs. loading) under cyclic
strain loading (0-7% at,
1Hz, 24hr)
AG CTS: Cells 
subjected to 25 mM D-
glucose for 84 hours 
under cyclic strain (0-
7% at 1Hz) and shear 
from flow loading(~ 0.3 
dynes.cm-2) 
Chronic high 
glucose 
CG U: Cells acclimated 
to 25 mM D-glucose for 
3-4 weeks before testing
and during mechanical
loading
CG CT: Cells 
acclimated to 25 mM D-
glucose for 3-4 weeks 
before testing and during 
mechanical loading 
under cyclic strain 
loading (0-7% at 1Hz) 
CG CTS: Cells 
acclimated to 25 mM D-
glucose for 3-4 weeks 
before testing and 
during mechanical 
loading under cyclic 
strain (0-7% at 1Hz) and 
shear from flow loading 
(~ 0.3 dynes.cm-2) 
Table 2.1: Experimental group summary 
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Cell Culture and Characterization: 
Fresh aorta from female Sprague-Dawley™ rats (8-10 weeks old) were obtained and were 
enzymatically digested to isolate smooth muscle cells in a modified two-step digestion method [183] 
(approved by Clemson University Institutional Animal Care and Use Committee). Briefly, isolated 
aorta was first treated with Dulbecco’s modified eagle medium MEM (5.5 mM, Corning 10-014-
CV or 25 mM D-Glucose, Corning 10-013-CM) containing collagenase type-II (300U/mL, 
Worthington 4176) and 1% antibiotic/antimycotic (Penicillin/streptomycin, Cellgro 30-004-CI) at 
370C for 15 minutes. This pretreatment with collagenase type-II enables easier removal of adventitia 
without overstretching the aorta. At the end of incubation, adventitial layer of aorta was removed 
under sterile conditions. Next, the aorta was split open longitudinally and its luminal surface was 
gently scrapped off to remove endothelial cells and finally was rinsed in PBS at 370C (Corning 46-
013-CM). Medial tissue was chopped into small squares (~1 mm wide) and transferred to the
digestion solution (DMEM +1% Ab/m with 5.5 mM or 25 mM D-Glucose) containing collagenase 
type-II (300 U/mL) and elastase (10 U/mL, Worthington 2292). Digestion solution containing tissue 
was transferred to a 6-well plate and incubated at 370C for about 2 hours with gentle intermittent 
shaking at every 30 minutes for 5 minutes. After incubation, the digestion solution was centrifuged 
at 1000 rpm for 5 minutes, the supernatant was aspirated and pellet was re-dissolved in DMEM (5.5 
mM or 25 mM D-Glucose) containing 10% fetal bovine serum ( ) and 1% Ab/m. Cells were cultured 
in DMEM containing normal (5.5 mM D-Glucose, LG) or high (25 mM D-Glucose, CG) until 
passage 6. Media was replaced every third day and cells became confluent every 10 days, beyond 
which they were passaged.  
Characterization of smooth muscle cells was performed by immunofluorescence staining for α-SM 
actin. Briefly, cells were fixed with ice-cold fixative [4% paraformaldehyde, 0.1% glutaraldehyde 
and 4% sucrose in calcium magnesium free PBS (Mediatech, CM-PBS)] and were subsequently 
treated with blocking solution [3% bovine serum albumin (Santa Cruz 9048-46-8), 3% Goat Serum 
(Sigma, G9023)] and 0.1% Triton X-100 (Sigma, T-8787) in CM-PBS). After wash cycles, cells 
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were incubated overnight at 40C with anti-SM alpha actin antibody (ab 7817, Abcam) diluted to 
1:100 in 3% BSA/PBS solution. After subsequent wash steps, cells were incubated with 
fluorescently tagged secondary antibody (A-11001, Life Technologies, diluted to 1:1000 in 
3%BSA/PBS solution) for 1 hour. Cellular nuclei were stained with DAPI (Molecular Probes, A-
21207, diluted to 1:3000 in PBS). Greater than 90% of the cells demonstrated to be α-SM actin 
positive.  
Cell Seeding and Application of Mechanical Force: 
For each experimental simulation, silicone membranes (diameter–6 cm) were cut from biomedical-
grade silicone sheets of 0.015 inch thickness and 40 durometer hardness (SMI, 0.15” NRV G/G 
40D). These were cleaned by sonication in deionized water and then autoclaved. A sterile station 
plate sandwich was formed using sterile station-rings and silicone membranes (Figure 2.1).  
The simulator design enables users to accommodate three of such assemblies on each baseplate (3 
loading stations per baseplate, figure 2.2a) and with two baseplate it provides a total sample size of 
6. Each sandwich assembly was placed on a loading post with 0.2 cc of silicone lubricant (Loctite,
51360) distributed evenly in between. Baseplate assembly was then UV-sterilized for 12 hours 
following which sterile Teflon rings (2.75 cm2 inner cross-sectional area and 1.2 cm height) were 
centered on the silicone surface exactly above the loading post. The surface area confined using the 
Teflon ring was then coated with collagen type-I (Advanced Biomatrix, 5005B) at a final 
concentration of 50 µg/mL using deionized water [184].  
Figure 2.1: Loading station with plate sandwich at center 
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Prior to cell seeding, each collagen coated silicone membrane assembly was rinsed with 1 mL of 
DPBS (Cellgro, 21-031-CV). P2-P5 VSMCs were trypsinized (Corning, 25-050-CI) and counted 
using scepter cell-counter (Millipore, PHCC00000) and seeded at a density of 1.8 x 104 cells/cm 2 
or 50,000 cells per well/loading station and allowed to attach and spread for 36 hours in media (5.5 
mM or 25 mM D-Glucose) containing 10% FBS and 1% Ab/Am at 37 0C.  After 36 hours, media 
was changed to DMEM (5.5 mM or 25 mM D-Glucose) containing 1% fetal bovine serum, 1% 
Ab/m and 1% Dextran (Sigma, 9004-54-0) to induce quiescence and adjust media viscosity 
respectively [184].  
Cells were subjected to either physiological cyclic strain (0-7%) at 1 Hz for 24 hours (CT) or to 
cyclic tensile strain and low wall shear stress (CTS, ~0.30 dynes.cm-2) from externally supplied flow 
at 350 mL/min using a peristaltic pump for 24 hours (CTS) (Figure 2.2b). 
Cells cultured in high glucose conditions (25 mM) represented acute hyperglycemia (AG). AG cells 
were subjected to mechanical loading with cyclic tensile (CT) and cyclic-tensile shear (CTS) for 24 
hours. Low glucose (5.5 mM) conditioned cells served as controls (LG). In addition, we also wanted 
to evaluate the phenotypic response of cells when preconditioned to high glucose conditions. 
a. b. 
Figure 2.2: a. Baseplate with 3 loading stations; b. External fluid supply with peristaltic 
pumps station with plate sandwich at center 
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Represented by chronic hyperglycemia (CG), this group was incorporated to analyze the phenotypic 
differences attributable to prolonged high glucose exposure.  
Cell Proliferation: 
Proliferative capacity of the cells was analyzed using a CyQuant proliferation assay kit (Promega, 
7026) using the manufacturer’s protocol. Briefly, cells were trypsinized from the silicone membrane 
post simulation. Cell pellets were collected and frozen at -70 0C. On the day of the assay, pellets 
were thawed at room temperature and resuspended in 200 µL of 1x-lysis buffer containing GR-
CyQuant dye at a final dilution of 80-fold. Each of the 200 µL samples were transferred to 96-black 
well plate and their fluorescence were recorded at an absorbance and emission maximum of 480 and 
520 nm respectively with a microplate reader (Gen 5, Biotek Synergy 4). Cell counts were estimated 
using a fluorescence and known cell count standard curve for a sample size of 6 per treatment.  
Apoptosis: 
Cell apoptosis was measured using the Dead-End Tunel assay kit (Promega, G3250) using the 
manufacturer’s protocol. This assay measures the fragmented DNA of apoptotic cells by 
catalytically incorporating fluorescin-12-dUTP at 3’-OH DNA ends using enzyme Terminal 
deoxynucleotidyl Transferase (rTdT) which forms a polymeric tail by nick end labeling. Briefly, 
cells were fixed with ice-cold fixative solution after each simulation for 15 minutes. Cells were then 
rinsed with 1x DPBS three times for 5 minutes per wash. Cells were permeabilized using 0.2 % 
triton X-100 (Fisher Bioreagents, 9002-93-1) in PBS for 5 minutes followed by three PBS rinses. 
Cells were then covered with 100 µL of equilibration buffer at room temperature for 10 minutes.  
After removing the equilibration buffer, 50 µL of the TdT reaction mix (45 µL equilibration buffer, 
5 µL nucleotide mix and 1 µL rTdT Enzyme) was used to cover the cells. In order to prevent reaction 
mix from drying out, small silicone membranes were used to cover the cells without any bubbles. 
Membranes were then incubated at 370C in a humidified chamber without any exposure to light. 
The reaction was stopped with 2x SSC buffer after 60 minutes of incubation. Finally, silicone 
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membranes were washed in PBS three times, 5 minutes per wash. Counterstaining was performed 
with propidium iodide (Sigma, P4864) or Phalloidin (P1951, Sigma) diluted to 1:1000 in PBS. 
TUNEL positive cells were observed with a fluorescent microscope (Digital inverted microscope, 
EVOS f1, AMG). Cells were imaged with three random field-of-view per sample with apoptotic 
and total number cells emitting green and red fluorescence respectively. Percentage of apoptotic 
cells [(Tunel positive cells/total cells)*100] was determined for each sample and was averaged for 
across each treatment with total sample size of 18 per treatment.  
Cellular Hypertrophy: 
Cells after each treatment were fixed with ice-cold 4% fixative solution for 15 minutes followed by 
rinsing with PBS and permeabilization with 0.2% Triton X-100 in PBS for 5 minutes. Subsequent 
washes with PBS were done, following which cells were incubated with rhodamine-phalloidin 
(P1951, Sigma) diluted to 1:1000 in PBS. After 15 minutes, cells were rinsed with PBS and were 
incubated with 1:2000 DAPI in PBS. Finally cells were imaged using fluorescent microscope 
(Digital inverted microscope, EVOS f1, AMG). For each sample, five to six random field-of-view 
were recorded and analyzed per sample resulting in a total sample size of 125 per treatment. Cell 
area and aspect ratio were measured using ImageJ software (NIH). Mean cell area (µm2) & aspect 
ratio (ratio of major axis length to minor axis length) were measured and analyzed for a sample size 
of 125 per treatment.   
Protein Expression: 
Quantification of contractile-state associated protein markers was performed using western blot. 
Briefly, protein was extracted from each sample using extraction buffer (10 µL/mL protease 
inhibitor cocktail, Sigma P 8340). Lysates were centrifuged at 14000g for 20 minutes at 40C, after 
which the supernatant was carefully removed and collected in fresh pre-chilled tubes. Total protein 
concentration was calculated using BCA-assay kit (Life Technologies, 23225) using BSA know 
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standards as described by manufacturer. For each lane 8 µg of protein was loaded on a 12% Tris-
SDS acrylamide gels under denaturing conditions. Electrophoresis was performed for 120 minutes 
at 100 V. PVDF membranes were used to blot the proteins at 100 V for 75 minutes. Blots were 
subsequently blocked in 3% BSA in PBS solution for 1 hour at room temperature. Blots were 
incubated overnight at 40C with respective primary antibody (SM α-actin ab 7817, 1:500; Calponin, 
ab 46794, 1:2000; SM-22α, ab10135 1:1500; α-tubulin, ab7291 1:2500), diluted in 3% bovine serum 
albumin blocking buffer . After subsequent wash steps, blots were incubated with respective horse- 
radish peroxidase (HRP) conjugated secondary antibody (1:5000 Anti-rabbit; 1:7500 Anti-goat; 
1:10000 anti-mouse) for 90 minutes at room temperature. Chemiluminescence substrate (Santa 
Cruz, SC-2048) was added prior to imaging of the blots and images were captured at approximately 
five minutes exposure setting. Densitometric analysis of the blots was performed with ImageJ 
software and α-tubulin served a loading control across all samples with a sample size of 6 per 
treatment.    
Statistical Analysis: 
Statistical Analysis was performed with One-way ANOVA and Tukey’s post hoc for all data sets. 
All tests were performed with Minitab® 17 (Minitab Inc.) 
2.3 Results: 
Smooth muscle cell characterization: 
More than 90% of the rat aortic smooth muscle cells, isolated from Spargue-Dawley™ rats by the 
described method, stained positive for SM α-actin as observed by Immunofluorescence (Figure 2.3). 
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Cell Proliferation: Cell number estimation was performed using the CyQuant cell proliferation 
assay. Results from CyQuant showed 40213 ± 5010 cells in LG U, 60301 ± 3568 cells in AG U, 
62472 ± 4593 cells in CG U, 28641 ± 2861 cells in LG CT, 44592 ± 5089 cells in AG CT, 33026 ± 
3455 cells in CG CT, 41625 ± 6500 cells in LG CTS, 58932 ± 5712 cells in AG CTS and 56137 ± 
1694 cells in CG CTS. Due to different glycemic levels (figure 2.4A), acute hyperglycemic cells 
demonstrated a significantly higher cell count as compared to low glucose controls under all 
mechanical conditions (p-value < 0.0001 for U, CT and CTS). Under chronic hyperglycemia, cell 
number increase was observed for all the loading conditions however significant differences were 
only observed for unloaded controls (p-value < 0.0001) and CTS samples (p < 0.0001). When 
comparing between different loading conditions (figure 2.4B), application of cyclic tensile led to a 
significant decrease in proliferation for all glycemic groups (p = 0.0017 for LG, p < 0.0001 for AG 
and CG). In addition, application of concomitant shear led to an increase in proliferation when 
compared to respective cyclic tensile condition for all low, acute and chronic high glucose (p = 
0.0003 for LG, p < 0.0001 for AG and CG). Difference in cell proliferation between unloaded 
conditions and CTS were non-significant. All statistical comparisons were performed using 
ANOVA and Tukey’s LSD method. Data values are summarized in table 2.2. 
Figure 2.3: Immunofluorescence staining for SM α-actin at passage 4. Nuclei were stained 
with DAPI. Image was captured at 100x magnification. Scale bar represents 400 µm.  
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Sample Unloaded (U) Cyclic Tensile (CT) Cyclic Tensile + Shear 
(CTS) 
Low glucose (LG) 40213 ± 5010 cells 28641 ± 2861 cells 41625 ± 6500 
Acute high (AG) 60301 ± 3568 cells 44592 ± 5089 cells 58932 ± 5712 
Chronic high (CG) 62472 ± 4593 cells 33026 ± 3455 cells 56137 ± 1694 cells 
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Figure 2.4: Values represented as Mean ± SD (error bar) with n = 6 for each sample. A). '*' 
represents p-value < 0.05 when compared to low glucose controls within each simulation group. 
'#' represents p-value < 0.05 for chronic samples when compared to acute high glucose samples 
within each simulation group. B). '*' represents p-value < 0.05 when compared to unloaded 
simulation, '#' represents p-value < 0.05 for cyclic-tensile shear samples when compared to cyclic 
tensile simulation for each glycemic group. All comparison performed with One-way ANOVA & 
Tukey post-hoc analysis.  
# 
Table 2.2: Data values for CyQUANT Assay (Cells count represented as Mean ± SD), n=6 
A 
B 
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Apoptosis: 
Images captured for each sample are represented in figure 2.5. Green fluorescence represents 
TUNEL positive cells whereas red fluorescence represents total cells in the respective field-of-view. 
For each field, both TUNEL positive cells and total number of cells were counted to estimate the 
percent apoptosis (TUNEL positive/Total number of cells *100) within each sample.  Results from 
dead-end TUNEL assay (Figure 2.6) showed the ratio of apoptotic cells to total number of cells to 
be 1.74 ± 0.32% in LG U, in 7.84 ± 2.66% AG U, 8.31 ± 4.48% in CG U, 1.41 ± 0.67% in LG CT, 
4.35 ± 1.10% in AG CT, 17.65 ± 2.06% in CG CT, 9.2 ± 5.26% in LG CTS, 12.23 ± 3.55% in AG 
CTS and 20.85 ± 3.55% in CG CTS samples. Data values are summarized in table 2.3.  
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Figure 2.5: Tunel Images for Low Glucose (left column), Acute High Glucose (Center Column) 
and Chronic High glucose (Right Column) with Unloaded (a-f), Cyclic Tensile (g-l) and Cyclic 
Tensile Shear (m-r). Green fluorescence represents Tunel labeled DNA fragments and red 
fluorescence represents counterstain at 100x magnification, Scale bar-400 µm 
a. b. c. 
d. e. f. 
g. h. i. 
j. k. l. 
m. n. o. 
p. q. r.
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Under acute hyperglycemia (figure 2.6A), VSMCs exhibited an increased number of apoptotic cells 
when compared to LG controls for unloaded conditions (p-value < 0.0001) and loaded conditions 
however, in case of mechanically loaded conditions statistical significance could not be achieved 
(p-value = 0.1 for CT, p-value = 0.08 for CTS). Similarly, chronic samples demonstrated a 
significantly higher number of apoptotic cells across all loading conditions in comparison to low 
glucose controls (p-value < 0.0001 for U, CT and CTS). Interestingly, chronic hyperglycemia led to 
an even higher number of apoptotic cells than acute hyperglycemia when subjected to mechanical 
loading in comparison to unloaded controls (p-value = 0.0001 for CT and CTS).  
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Figure 2.6: Values represented as Mean ± SD (error bar) with n = 18 for each sample. A). '*' 
represents p-value < 0.05 when compared to low glucose controls within each simulation group. 
'#' represents p-value < 0.05 for chronic samples when compared to acute high glucose samples 
within each simulation group. B). '*' represents p-value < 0.05 when compared to unloaded 
simulation, '#' represents p-value < 0.05 for cyclic-tensile shear samples when compared to cyclic 
tensile simulation for each glycemic group. All comparison performed with One-way ANOVA & 
Tukey post-hoc analysis.  
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# 
# 
A
B
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Sample Unloaded (U) Cyclic Tensile (CT) Cyclic Tensile + Shear 
(CTS) 
Low glucose (LG) 0.74 ± 0.32% 1.41 ± 0.67% 9.2 ± 5.26% 
Acute high (AG) 7.84 ± 2.66% 4.35 ± 1.10% 12.23 ± 3.55% 
Chronic high (CG) 8.31 ± 4.48% 17.65 ± 2.06% 20.85 ± 3.55% 
When comparing between different loading conditions (figure 2.6B), application of cyclic tensile 
led to a significant increase only for chronic high glucose treatment (p < 0.0001) in comparison to 
respective unloaded control. In contrast, application of cyclic tensile led to a decrease in percent 
apoptosis (p = 0.0247). Application of concomitant shear led to an increase in apoptosis when 
compared to respective cyclic tensile condition for all low and acute high glucose (p < 0.0001 for 
LG, p < 0.0001 for AG) with non-significant difference for chronic high glucose (p =0.0560). In 
comparison to unloaded conditions, application of CTS led to an increase in apoptosis for low (p < 
0.0001), acute (p <0.0012) and chronic (p < 0.0001) treatment.  
Cellular Hypertrophy: 
Rhodamine-phalloidin was used to stain the F-actin fibers of VSMCs for each sample. Images were 
counterstained with DAPI and were captured using a fluorescent microscope (figure 2.7). Images 
for respective glycemic group are arranged column-wise with LG in left, AG in center and CG at 
right. Different rows represent mechanical loading conditions with unloaded in the top, cyclic tensile 
in the center and cyclic-tensile shear in the bottom row. From these images, it can be clearly 
appreciated that hyperglycemia led to an increase in cellular hypertrophy since low glucose sample 
appear to have more elongated morphology.  For each sample, five to six random field-of-view were 
recorded and analyzed per sample resulting in a total sample size of 125 per treatment.  Mean of cell 
area was observed to be 4003 ± 704 µm2 for LG U, 4978 ± 826 µm2 for AG U, 5494 ± 705 µm2 for 
CG U, 2312 ± 601 µm2 for LG CT, 2444 ± 1194 µm2 for AG CT, 2515± 814 µm2 for CG CT, 3545 
± 705 µm2 for LG CTS, 4232 ± 959 µm2 for AG CTS and 5082 ± 799 µm2 for CG CTS. With 
Table 2.3: Data values for DeadEnd-TUNEL Assay (% Apoptotic Cells represented as Mean ± 
SD), n=18 
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different glycemic conditions (figure 2.8A), mean value of cell area was significantly greater for 
chronic high glucose treatment in unloaded control (p-value < 0.0001) and CTS samples (p < 
0.0001) whereas for acute hyperglycemic conditions cell area was observed to be higher than low 
glucose controls under unloaded and CTS however, statistical significance was not observed. 
Application of cyclic tensile resulted in similar mean cell area values for all glycemic conditions.  
Figure 2.7: Rhodamine-Phalloidin Images for Low Glucose (left column), Acute High Glucose 
(Center Column) and Chronic High glucose (Right Column) with Unloaded (A-C), Cyclic Tensile 
(D-F) and Cyclic Tensile Shear (G-I) at 100x magnification, Scale bar-400 µm. 
A. B. C. 
D. E. F. 
G. H. I.
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Figure 2.8: Values represented as Mean ± SD (error bar) with n = 125 for each sample. A). 
'*' represents p-value < 0.05 when compared to low glucose controls within each simulation 
group. '#' represents p-value < 0.05 for chronic samples when compared to acute high glucose 
samples within each simulation group. B). '*' represents p-value < 0.05 when compared to 
unloaded simulation, '#' represents p-value < 0.05 for cyclic-tensile shear samples when 
compared to cyclic tensile simulation for each glycemic group. All comparison performed 
with One-way ANOVA & Tukey post-hoc analysis. 
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With different loading conditions (figure 2.8B), application of cyclic tensile strain led to a 
significant decrease in cell area for all glucose treatments (p < 0.0001 for LG, AG and CG) as 
compared to respective unloaded controls. In addition, application of cyclic tensile shear led to an 
increase in cell area for all glucose treatments (p < 0.0001 for LG, AG and CG). However, 
differences in cell area for unloaded and CTS were non-significant for all glucose treatments. Data 
values for cell area are summarized in table 2.4. 
Sample Unloaded (U) Cyclic Tensile (CT) Cyclic Tensile + Shear 
(CTS) 
Low glucose (LG) 4003 ± 704 µm2 2312 ± 601 µm2 3545 ± 705 µm2 
Acute high (AG) 4978 ± 826 µm2   2444 ± 1194 µm2 4232 ± 959 µm2 
Chronic high (CG) 5494 ± 705 µm2 2515± 814 µm2 5082 ± 799 µm2 
Table 2.4: Data values for Cell area (represented as Mean ± SD µm2), n=125 
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Cell Aspect ratio (AR), which is a ratio of major axis length to minor axis length of a cell, was 
observed to be 2.69 ± 0.62 for LG U, 1.98 ± 0.74 for AG U, 1.81 ± 0.33 for CG U, 3.08 ± 0.98 
for LG CT, 2.52 ± 0.79 for AG CT, 2.76 ± 0.93 for CG CT, 3.03 ± 0.83 for LG CTS, 1.73 ± 
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Figure 2.9: Values represented as Mean ± SD (error bar) with n = 125 for each sample. A). 
'*' represents p-value < 0.05 when compared to low glucose controls within each simulation 
group. '#' represents p-value < 0.05 for chronic samples when compared to acute high glucose 
samples within each simulation group. B). '*' represents p-value < 0.05 when compared to 
unloaded simulation, '#' represents p-value < 0.05 for cyclic-tensile shear samples when 
compared to cyclic tensile simulation for each glycemic group. All comparison performed 
with One-way ANOVA & Tukey post-hoc analysis. 
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0.36 for AG CTS and 1.96 ± 0.42 for CG CTS. For different glycemic conditions (figure 2.9A), 
mean aspect ratio for CT samples was observed to be nearly the same. Chronic hyperglycemic 
samples demonstrated a significantly lower aspect ratio under CTS loading conditions (p-value 
< 0.0001) and unloaded control (p-value < 0.0001) when compared to low glucose control. 
Acute hyperglycemia demonstrated a reduced mean aspect ratio across all treatments in 
comparison to low glucose controls, albeit statistical significance was only achieved in case of 
CTS treatment (p-value = 0.0001). With different loading conditions (figure 2.9B), application 
of cyclic tensile strain led to an increase in aspect ratio across all glucose treatments although 
significant increase was only observed in case of chronic high glucose ( p < 0.0001) in 
comparison to respective unloaded controls. Application of cyclic tensile-shear led to a 
significant increase only in case of acute and chronic high glucose in comparison to cyclic 
tensile conditions (p < 0.0001 for both AG and CG). However, in comparison to unloaded 
controls, no significant changes were observed for all glucose treatments.  Data values for cell 
aspect ratio are summarized in table 2.5.  
Sample Unloaded (U) Cyclic Tensile (CT) Cyclic Tensile + Shear 
(CTS) 
Low glucose (LG) 2.69 ± 0.62 3.08 ± 0.98 3.03 ± 0.83 
Acute high (AG) 1.98 ± 0.74 2.52 ± 0.79 1.73 ± 0.36 
Chronic high (CG) 1.81 ± 0.33 2.76 ± 0.93 1.96 ± 0.42 
Quantification of Protein Markers 
Expression levels of contractile-state associated proteins were compared with western blotting. 
Markers evaluated in the current study included SM α-Actin, Calponin and SM 22α. Expression 
levels of these proteins were normalized to the expression of α-tubulin. SM α-actin expression 
levels (figure 2.10) were significantly less for acute hyperglycemic samples for CTS loading (p-
value = 0.0001) and unloaded controls (p-value = 0.003). Similarly, chronic samples also had 
Table 2.5: Data values for Cell aspect ratio (represented as Mean ± SD), n=125 
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reduced expression of SM α-actin under CTS (p-value = 0.0001) and unloaded controls however 
statistical significance for unloaded controls was not reached. Expression levels of actin did not 
differ between different glycemic groups. 
    LG U    AG U    CG U    LG CT   AG CT   CG CT  LG CTS  AG CTS   CG CTS 
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Figure 2.10: Values represented as Mean ± SD (error bar) with n = 6 for each sample. A). '*' 
represents p-value < 0.05 when compared to low glucose controls within each simulation 
group. '#' represents p-value < 0.05 for chronic samples when compared to acute high glucose 
samples within each simulation group. B). '*' represents p-value < 0.05 when compared to 
unloaded simulation, '#' represents p-value < 0.05 for cyclic-tensile shear samples when 
compared to cyclic tensile simulation for each glycemic group. All comparison performed 
with One-way ANOVA & Tukey post-hoc analysis. U = Unloaded, CT = Cyclic Tensile, CTS 
= Cyclic Tensile shear; LG = low glucose, AG = acute high glucose, CG = chronic high 
glucose 
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With different loading conditions, application of cyclic tensile shear results in a significant 
decrease in alpha-actin for chronic high glucose (p = 0.0077) only as compared to unloaded 
condition. In contrast, application of cyclic tensile-shear led to an increase in actin expression as 
compared to unloaded conditions in case low glucose however, difference was non-significant 
(p = 0.298).  
Expression levels of calponin (figure 2.11A) were in agreement with low SM α-actin levels as 
chronic and acute samples exhibited reduced expression across unloaded and CTS in comparison 
to low glucose controls however, significant difference was only observed for chronic samples 
(p-value = 0.0002 for U, p-value < 0.0001 for CTS). In addition, calponin expression was 
observed to be significantly reduced for chronic samples even in comparison to acute 
hyperglycemia (p-value = 0.0208 for U, p-value = 0.0001 for CTS). For cyclic tensile only, there 
was marked reduction in calponin expression for chronic sample when compared to both low 
glucose controls (p-value < 0.0001) and acute high glucose (p-value = 0.0084). Between different 
loading conditions (figure 2.11B), there was a decrease in calponin expression between unloaded 
and cyclic tensile shear samples for low glucose and chronic high treatments however, significant 
differences were not observed.  
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Figure 2.11: Values represented as Mean ± SD (error bar) with n = 6 for each sample. A). 
'*' represents p-value < 0.05 when compared to low glucose controls within each simulation 
group. '#' represents p-value < 0.05 for chronic samples when compared to acute high 
glucose samples within each simulation group. B). '*' represents p-value < 0.05 when 
compared to unloaded simulation, '#' represents p-value < 0.05 for cyclic-tensile shear 
samples when compared to cyclic tensile simulation for each glycemic group. All comparison 
performed with One-way ANOVA & Tukey post-hoc analysis. U = Unloaded, CT = Cyclic 
Tensile, CTS = Cyclic Tensile shear; LG = low glucose, AG = acute high glucose, CG = 
chronic high glucose. 
34 KDa 
49 KDa 
* 
* 
* 
# # 
# 
51 
SM22α expression levels (figure 2.12A) remained nearly the same under all glycemic conditions 
for unloaded controls. However, application of mechanical forces led to a significantly reduced 
expression of SM22α under both acute (p-value = 0.0259 for CT, p-value =0.0002 for CTS) and 
chronic hyperglycemia (p-value = 0.0210 for CT, p-value = 0.0008 for CTS) in comparison to low 
glucose controls. 
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Figure 2.12: Values represented as Mean ± SD (error bar) with n = 6 for each sample. A). '*' 
represents p-value < 0.05 when compared to low glucose controls within each simulation 
group. '#' represents p-value < 0.05 for chronic samples when compared to acute high glucose 
samples within each simulation group. B). '*' represents p-value < 0.05 when compared to 
unloaded simulation, '#' represents p-value < 0.05 for cyclic-tensile shear samples when 
compared to cyclic tensile simulation for each glycemic group. All comparison performed 
with One-way ANOVA & Tukey post-hoc analysis. U = Unloaded, CT = Cyclic Tensile, CTS 
= Cyclic Tensile shear; LG = low glucose, AG = acute high glucose, CG = chronic high 
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With different glycemic conditions (figure 2.12B), application of cyclic tensile and cyclic tensile-
shear resulted a significant increase in expression of SM22 alpha (p = 0.014 for CT, p = 0.0002 for 
CTS) in comparison to unloaded controls. However, differences were not significant for acute and 
chronic high glucose treatments for all loading conditions.   
2.4 Discussion 
Hyperglycemia is a clinical metabolic complication associated with diabetic patients and poor 
glycemic control has been associated with poor outcomes of percutaneous coronary intervention, 
for both angioplasty and stents [138-140, 185-187]. Effects of mechanical forces under 
hyperglycemic conditions have not been explored and thus, using a vascular simulator capable of 
concomitant strain and shear application [188], we explored the influence of hyperglycemia on 
phenotypic modulation of rat aortic SMCs under mechanically loaded conditions.  
Clinically, VSMCs experience mechanical forces such as cyclic strain due to arterial distension and 
compression in addition to shear forces from blood flow, which come into play after denudation of 
the endothelium or migration of VSMCs to the intima. Using 3D-reconstruction and mesh approach, 
Garcia and collaborators [64] and LaDisa and collaborators [176] demonstrated neointimal growth 
to be negatively correlated with shear stress in the intra-stent regions in humans and animal models 
respectively. Phenotypic modulation of vascular smooth muscle cells is one of the early cellular 
response to the barotrauma from a PCI procedure resulting in a migratory and proliferative synthetic 
phenotype which contributes to neointimal hyperplasia [166]. Phenotypic modulation of VSMCs 
from a contractile to a synthetic state is associated with increased proliferation, increased cellular 
hypertrophy, decreased expression contractile-state associated proteins including SM-α actin, 
SM22-α, and calponin [168].  
In the current study, we investigated the effects of different glycemic conditions on passage 2-5 rat 
aortic smooth muscle cell phenotype when subjected to different mechanical loading conditions. 
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Glycemic conditions investigated were low glucose or LG (5.5 mM glucose during seeding and 
mechanical loading), acute high glucose or AG (25 mM glucose during seeding and mechanical 
loading) and chronic high glucose or CG (cells acclimated with 25 mM glucose for 3-4 weeks before 
testing and during mechanical loading). Mechanical loading conditions included unloaded or U 
(static), cyclic tensile or CT (0-7% cyclic stretch at 1Hz for 24 hours) and cyclic tensile shear or 
CTS (0-7% cyclic stretch at 1Hz and ~ 0.30 dynes.cm-2 shear stress for 24 hours). Characterization 
of SMC phenotypic modulation was performed by evaluating changes in cellular proliferation, 
percentage of apoptotic cells, cellular hypertrophy estimated by comparing average of cell area and 
aspect ratio of imaged cells across all samples and comparing the expression levels of contractile-
state associated markers.  
Within the smooth muscle cell continuum, synthetic cells have been shown to exhibit greater rates 
of proliferation as compared to contractile phenotype. Application of physiological levels of strain 
have been reported to cause cell cycle arrest thereby inhibiting VSMC proliferation [189]. Results 
from our study are in agreement with previous work since application of cyclic strain led to an 
overall decrease in cellular proliferation as compared to unloaded control whereas concomitant 
application of shear and strain resulted in an increased proliferative response in comparison to cyclic 
strain [188]. In the current study, exposure of hyperglycemic samples to concomitant shear and 
strain led to a significant increase in proliferation when compared to low glucose samples (p < 
0.0001 for acute or AG; p < 0.0001 for chronic or CG). These results indicate that hyperglycemia is 
contributive to VSMC proliferation. Previous studies have demonstrated a proliferative response 
exhibited by VSMCs under high glucose conditions and  cell-proliferation results for the unloaded 
controls (U) from our study are in accordance with them (p < 0.0001 for AG; p < 0.0001 for CG) 
[158]. However, to the best of our knowledge, increased proliferation under hyperglycemia in 
response to concomitant shear and strain has not been reported before. Although, mechanisms 
involved in increasing proliferation under mechanically loaded conditions were not explored in our 
study, it is evident from current results that exposure of VSMCs to high glucose conditions and 
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mechanical forces led to an increased proliferation in comparison to low glucose conditions, which 
may be indicative of increased phenotypic modulation in hyperglycemic groups. Wire injury in 
streptozotocin-induced diabetic mice has been shown to cause an increased neointimal hyperplasia 
attributed to hyperglycemia-mediated SMC growth and proliferation [181]. Further, in vitro studies 
with arterial and venous smooth muscle cells from diabetic patients have also demonstrated an 
increased proliferation of VSMCs, as compared to non-diabetic controls [190, 191]. Consistent with 
these studies, results from our study also indicate a similar response, of increased proliferation, 
exhibited by cells subjected to CTS conditions under hyperglycemia thus supporting the relevance 
of this dynamic disease model designed to subject VSMCs, cultured in different glycemic 
conditions, to clinically relevant mechanical forces. 
In addition to proliferation, VSMC apoptosis also plays a critical role in neo-intimal formation after 
vessel injury. Studies have reported a rapid apoptosis after angioplasty with up to 70% of VSMCs 
becoming apoptotic within 90 minutes [192]. In mouse flow cessation studies, VSMC apoptosis was 
shown to cause migration, proliferation and extracellular matrix secretion of neighboring VSMCs 
and led to a thicker neo-intima despite significant apoptosis. These results were shown to be 
mediated by IL-6 release which has been shown to cause VSMC proliferation and promote 
migration [193]. Similarly, in rat models of balloon-injury, medial cells have been shown to undergo 
apoptosis from 30 min to 4 hours post-dilation [194]. Although the exact contribution of apoptosis 
to the development of neo-intimal hyperplasia is unclear, it still represents one of the earliest 
response of the resident cells. Thus, an apoptotic response can be correlated with increased 
synthetic-state characteristics since higher proliferation and apoptosis may also represent a higher 
cell turnover rate associated with dedifferentiation [184].  Results from the current study illustrate 
an increase in percentage of apoptotic cells under both acute and chronic hyperglycemia across all 
mechanical loading conditions in comparison to low glucose controls, however statistical 
significance for acute CTS was not observed (p = 0.0842). Further, apoptosis was reported to be 
higher for CTS loading in all glycemic conditions in comparison to CT. These results indicate that 
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hyperglycemia and mechanical forces are contributive to apoptosis and this response is more 
pronounced with the application of low shear stress. Low shear stress led to an increased overall 
apoptotic capacity even in low glucose samples, although significantly less than chronic samples (p 
< 0.0001). In vitro application of low shear stress has been shown to increase Rac1-Rho 
phosphorylation in VSMCs [195]. This, in part, may explain the role of low shear in mediating a 
pro-apoptotic behavior [196]. Another mechanism that may contribute to increased apoptosis is 
hyperglycemia-mediated reactive oxygen species generation which has been implicated as a 
contributor to VSMC apoptosis via upregulation of hydrogen peroxide in other studies [197].  
Cellular hypertrophy, indicative of increased cell size, has been employed as an estimate of 
phenotypic modulation since synthetic state cells are generally more rhomboid/epithelioid-shaped 
as compared to spindle-like contractile cells.  In addition, an organized F-actin structure, which is 
involved in maintaining contractile functions, is associated with the contractile-state phenotype 
whereas a diffuse loose F-actin structure is exhibited by synthetic cells [198].  Estimation of cellular 
hypertrophy by measuring average cell area of imaged cells revealed a greater cell area under both 
acute and chronic hyperglycemic conditions compared to low glucose samples in unloaded controls 
as well as in CTS simulations, however the differences for were significant only for CG U( p< 
0.0001) and CG CTS ( p < 0.0001) compared to LG U and LG CTS respectively. Further, application 
of cyclic strain led to an overall decrease in cell area across all samples thus demonstrating the 
influence of concomitant shear and strain on cell morphology. In agreement with the results of 
increased cell area, mean cell aspect ratio was also observed to be lower for both AG U and CG U 
(p<0.0001 for CG U only, non-significant for AG U) compared to LG U with lower aspect ratio for 
AG CTS and CG CTS loading (p<0.0001 for AG, p < 0.0001 for CG) in comparison to LG CTS. 
These results indicate an increased cellular hypertrophy of VSMCs under both short and long term 
hyperglycemic conditions compared to low glucose CTS controls. Results of cellular hypertrophy 
from previous studies have demonstrated similar effects, with application of strain and shear 
resulting in an overall decrease in aspect ratio, thus subordinating our CTS results [188]. VSMCs 
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from diabetic patients have been reported to attain an altered and rhomboid-shape cell shape with a 
loss of the typical ‘hill-valley’ morphology as compared to non-diabetic controls [190, 191] and 
these morphological changes have been consistent in neo-intimal lesions  [199]. These studies are 
in agreement with our observations where high glucose conditions resulted in a more rounded 
morphology leading to a lower cell aspect ratio thus supporting the relevance of our dynamic disease 
model. 
Expression levels of contractile-state associated proteins is one of the most important distinguishing 
markers of SMC phenotype. As mentioned before, contractile state of VSMCs is characterized by 
greater expression of contractile-apparatus proteins and in the current study we evaluated the 
expression levels of SM α-actin, SM22 α and calponin normalized to α-tubulin. With cyclic strain, 
nearly the same SM α-actin expression levels were observed for all three glycemic groups. 
Interestingly with cyclic strain, calponin and SM22α levels were significantly reduced for chronic 
samples (p < 0.0001 for calponin, p = 0.0210 for SM22α) whereas significance was only observed 
for SM22α in case of acute conditions (p = 0.0259), in comparison to low glucose CT. Further, 
chronic glucose (CG) led to a significantly decreased expression of SM α-actin, SM22 alpha and 
calponin under CTS condition (p < 0.0001, p = 0.0008, p < 0.0001 respectively) in comparison to 
LG CTS. In addition, CG CTS led to a lower expression of actin and calponin, but not SM22α in 
comparison to AG CTS, however significant reduction was only observed in calponin expression (p 
<0.0001). Thus, both acute and chronic hyperglycemic samples exhibited a more synthetic 
phenotype in comparison to low glucose controls under CTS, with chronic hyperglycemia resulting 
in a relatively greater synthetic response as estimated from significantly lower levels of SM α-actin 
and calponin expression in chronic CTS (CG CTS). Protein expression results from previous studies 
have demonstrated a reduction in SM α-actin and calponin in VSMCs isolated from rat models of 
type 1 diabetes [200, 201] and type 2 diabetes [202] respectively. These results are in agreement 
with our observation of reduced expression levels of all three markers (SM α-actin, SM22 α and 
calponin) in chronic hyperglycemic samples subjected to clinically relevant mechanical forces in 
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our dynamic disease model. Thus, concomitant application of shear and strain to vascular smooth 
muscle cells subjected to chronic hyperglycemia led to an overall increase the synthetic activity of 
cells as evident from increased proliferation and apoptosis, cellular hypertrophy and decreased 
expression of contractile-state associated markers thereby providing conclusive results to prove our 
proposed hypothesis. In future, this model could be used to evaluate novel drugs aimed at reducing 
restenosis in diabetes or compare the efficacy of existing drugs.  
2.5 Conclusion 
In the current study we assessed the relative differences in phenotypic modulation of vascular 
smooth muscle cells due to mechanical loading and hyperglycemia by comparing cellular 
proliferation, apoptosis, hypertrophy and expression of contractile-state markers. Results from the 
study indicate a direct contribution of hyperglycemia to phenotypic modulation of SMCs in acute 
and chronic samples. With cyclic strain only conditions, nearly the same response was observed in 
acute and chronic samples with slight evidence of de-differentiation observed as compared to low 
glucose controls & no significant difference between acute and chronic samples. However, 
application of low shear with cyclic strain (CTS) led to a significant difference in the response of 
all groups with acute (AG CTS) and chronic (CG CTS) samples eliciting a relatively greater 
phenotypic modulation in comparison to respective low glucose control (LG CTS). Thus, these 
results indicate that only low shear stress may be contributive to glycaemia-mediated phenotypic 
modulation. In addition, although differences between acute and chronic samples were not similar 
for all assays, chronic samples did express higher rates of apoptosis consistently. Importantly, we 
did not explore the potential mechanisms involved in manifestation of these effects and thus 
exploration of the mechanisms will require further research. In conclusion, increased phenotypic 
modulation was observed for hyperglycemic VSMCs subjected to low shear stress and cyclic strain 
(CTS) with increased apoptosis for chronic hyperglycemia across all loading conditions. Similarity 
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of VSMC response between our model and diabetes-associated phenotypic changes support the 
relevance of our model. This model may serve a useful role in exploring the effects of diabetes-
related metabolic complications at a cellular levels in conjunction with precisely controlled 
hemodynamics.  
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Project Recommendations: 
1. Application of this model can be extended to response evaluation of other metabolic-
complications and mechanical forces. Clinically, insulin treated diabetic patients are at
increased risk of developing MACE (Major adverse cardiac events) and TVF even with use of
second generation drug eluting stents. Thus, this model can be utilized in evaluating the
response to insulin mediated VSMC response to low shear forces. In addition to exploring
phenotypic modulation, this models can be applied to inflammatory cells in applications such
as increased inflammatory markers in the circulating media or macrophage-conditioned media
and their contribution to the VSMC response.
2. Using the same bioreactor system, efficacy of different anti-restenotic drugs can be compared
in reference to altered hemodynamics such as paclitaxel, sirolimus or exogenous administration
of nitric oxide on VSMC phenotypic modulation in altered hemodynamics and diabetes-related
metabolic environment. However, drug administration approach should closely mimic the
kinetics of the drug in vivo.
3. In order to increase the clinical relevance of the current model, lid designs can be exploited to
reduce channel height which would enable the application of physiological and high shear
stresses and thus compare responses in normal and diseased milieu.
4. In the current study, type 1 collagen was used as the seeding matrix for VSMCs.
Mechanotransduction is also influenced by the type of ECM and this model can be used to
compare cellular response of different ECM matrices and can also be extended to evaluate the
response on modified matrices such as glycated ECM molecules to improve our current
understanding of diabetes.
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